At an Extraordinary General Meeting on Friday, Jean-Luc Butel, Senior Advisor at McKinsey & Company Healthcare Systems & Services, and Fran-cis Cuss, former Executive Vice President and Chief Scientific Officer of Bristol-Myers Squibb, were elected as new members of the Board of Direc-tors of Novo Holdings A/S.

Sten Scheibye, Chairman of the Board of Directors of Novo Holdings, says: “I am delighted that Jean-Luc Butel and Francis Cuss are joining the Board of Novo Holdings. They both bring profound business experience and comprehensive insights from their impressive international careers in the life-science sector. This will strengthen and further develop Novo Holdings as we aim to increase our investments in the life sciences.”

Novo Holdings is the holding and investment company of the Novo Group with total assets of DKK 275.7 billion (USD 43.6 billion) as of the end of 2016. Novo Holdings is wholly owned by the Novo Nordisk Foundation and currently wholly or partly owns more than 80 life-science companies, many of which are headquartered in the United States. Last year, the company invested DKK 8.7 billion (USD 1.37 billion) in life-science companies. The strategy of Novo Holdings is to substantially increase its investments in life-science companies over the coming years.